BiomX Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $9.2 million, compared to a net income of $9.6 million in the same period of 2024. The company’s operating loss for the quarter was $8.5 million, a decrease from the $11.3 million loss reported in the prior year. For the nine months ending September 30, 2025, BiomX's net loss totaled $22.9 million, significantly higher than the $3.2 million loss recorded during the same timeframe in 2024. The increase in losses is attributed to higher research and development expenses, which amounted to $16.4 million for the nine months, down from $18.3 million in 2024.
In terms of liquidity, BiomX's cash and cash equivalents decreased to $6.9 million as of September 30, 2025, down from $16.9 million at the end of 2024. The company’s total current assets also fell to $8.9 million from $20.5 million, while total stockholders' equity decreased to $10.5 million from $24.1 million. The decline in cash reserves and equity reflects the ongoing investment in research and development and operational costs, as well as the impact of the company's strategic decisions.
BiomX has been actively pursuing strategic developments, including the acquisition of Adaptive Phage Therapeutics (APT) in March 2024, which has expanded its pipeline to include two Phase 2 assets targeting serious bacterial infections. The company has also undergone organizational changes, including a reverse stock split effective August 26, 2024, aimed at improving its stock price and market perception. Additionally, BiomX is in the process of liquidating its subsidiary, RondinX Ltd., which had no significant operations as of August 2025.
Operationally, BiomX has focused on developing phage-based therapies for chronic diseases, particularly cystic fibrosis and diabetic foot infections. The company continues to monitor the geopolitical situation in Israel, where it is headquartered, but reports that the ongoing conflict has not materially impacted its operations. BiomX's employee headcount remains stable, and the company is committed to advancing its clinical programs despite the challenging market conditions.
Looking ahead, BiomX anticipates that its current funds will support operations into the first quarter of 2026. However, the company acknowledges the need for additional funding to sustain its research and development efforts and to address potential increases in operational expenses. The management has expressed confidence in its ability to raise capital through various means, including debt and equity securities, but recognizes the uncertainties posed by market conditions and geopolitical factors.
About BiomX Inc.
BiomX Inc. is a clinical-stage biotechnology company developing phage-based therapies that target harmful bacteria linked to chronic diseases like cystic fibrosis and diabetic foot osteomyelitis. Utilizing proprietary platforms—BOLT for engineered phage cocktails and PST for personalized phage matching—BiomX designs natural and synthetic bacteriophage treatments. Its business model focuses on precise bacterial targeting to address antibiotic resistance, serving patients through clinical development and potential future commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov